Nanoparticulate drug delivery for therapeutic applications
Summary
The USPTO granted Patent US12594347B2 to Duke University for compositions comprising self-assembling conjugates designed for nanoparticulate drug delivery. The patent covers conjugates with albumin binding domains and molecules having log D ≥ 1.5 at pH 7.4, intended for therapeutic applications including cancer treatment (A61P 35/00). Assignee: Duke University; Inventors: Parisa Yousefpour, Ashutosh Chilkoti.
What changed
The USPTO granted Patent US12594347B2 to Duke University for a nanoparticulate drug delivery system comprising self-assembling conjugates with a polypeptide (transition temperature >50°C), an albumin binding domain, and a cysteine-linked molecule (log D ≥1.5). The patent contains 16 claims and covers compositions for therapeutic applications, including cancer treatment. The technology enables targeted drug delivery through temperature-sensitive self-assembly and albumin-mediated transport.
This is a routine patent grant notification and does not impose compliance obligations on third parties. Pharmaceutical companies and researchers developing drug delivery systems may wish to review the patent claims to assess potential licensing needs or design-around considerations. The patent provides Duke University with exclusive rights to the technology through the grant date.
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Nanoparticulate drug delivery systems
Grant US12594347B2 Kind: B2 Apr 07, 2026
Assignee
Duke University
Inventors
Parisa Yousefpour, Ashutosh Chilkoti
Abstract
Described herein are compositions that include an assembly of self-assembling conjugates. The self-assembling conjugates may include a polypeptide having a transition temperature (17) above 50° C. when the polypeptide is not attached to the conjugate, an albumin binding domain (ABD) attached to a first end of the polypeptide, and at least one molecule attached to a second end of the polypeptide through a cysteine group, wherein the molecule has an octanol-water distribution coefficient (log D) of greater than or equal to 1.5 at a pH of 7.4 when the molecule is not attached to the conjugate. Also described herein are methods of using the compositions.
CPC Classifications
A61K 47/6907 A61K 47/64 A61K 49/0041 A61K 49/0056 A61K 49/0082 A61P 35/00 C07K 2319/00 C07K 14/315
Filing Date
2019-09-06
Application No.
17272887
Claims
16
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.